14, 5% af patienterne behandlet med Enbrel reaktioner på injektionsstedet i løbet af de første 12 ugers behandling sammenlignet med 5, 2% af patienterne behandlet med placebo.
In controlled trials in patients with plaque psoriasis, approximately 14.5% of patients treated with Enbrel developed injection site reactions compared with 5.2% of placebo-treated patients during the first 12 weeks of treatment.